Basics Atossa Therapeutics, Inc. Atossa Genetics Inc mainly focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. IPO Date: November 8, 2012 Sector: Healthcare Industry: Biotech Market Cap: $118.16M Activated in VL: True Average Daily Range Avg Daily Range: $0.09 | 4.37% Avg Daily Range (30 D): $0.02 | 2.82% Avg Daily Range (90 D): $0.03 | 3.88% Institutional Daily Volume Avg Daily Volume: 1.74M Avg Daily Volume (30 D): .66M Avg Daily Volume (90 D): .61M Trade Size Avg Trade Size (Sh.): 365 Avg Trade Size (Sh.) (30 D): 284 Avg Trade Size (Sh.) (90 D): 267 Institutional Trades Total Inst.Trades: 168 Avg Inst. Trade: $2.14M Avg Inst. Trade (30 D): $3.98M Avg Inst. Trade (90 D): $3.98M Avg Inst. Trade Volume: .6M Avg Inst. Trades (Per Day): 1 Market Closing Trades Avg Closing Trade: $5.33M Avg Closing Trade (30 D): $9.36M Avg Closing Trade (90 D): $9.36M Avg Closing Volume: 1.6M     News Oct 14, 2024 @ 9:08 PM Atossa Therapeutics to Present at the 2024 Maxim H... Source: N/A Jun 28, 2024 @ 12:30 PM Atossa Therapeutics Announces Updated Protocol for... Source: Atossa Therapeutics, Inc. Jun 25, 2024 @ 1:40 PM Are Medical Stocks Lagging Alvotech (ALVO) This Y... Source: Zacks Equity Research Jun 17, 2024 @ 12:30 PM Atossa Set to Join Russell 3000® Index Effectiv... Source: Atossa Therapeutics, Inc. Jun 6, 2024 @ 1:40 PM Is Atossa Genetics (ATOS) Stock Outpacing Its Medi... Source: Zacks Equity Research Financials   TTM Q1 2025 Q4 2024 Basic EPS $-.21 $-.05 $-.05 Diluted EPS $-.21 $-.05 $-.05 Revenue $ M $ M $ M Gross Profit $ $ $ Net Income / Loss $ -26.34M $ -6.72M $ -6.35M Operating Income / Loss $ -28.06M $ -7.41M $ -7.15M Cost of Revenue $ $ $ Net Cash Flow $ -12.88M $ M $ -3.68M PE Ratio     Splits Apr 20, 2018:   1:12 Aug 26, 2016:   1:15